Limits...
Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11bGr-1 Myeloid-derived Suppressor Cells.

Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY - Immune Netw (2010)

Bottom Line: Intriguingly, anti-CD137 mAb injection significantly increased CD11b(+)Gr-1(+) cells, peaking at days 5 to 10 and continuing for at least 25 days.Furthermore, this cell population could suppress both CD8(+) T cells and CD4(+) T cells.Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce CD11b(+)Gr-1(+) MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea.

ABSTRACT
CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress CD4(+) T cells, ameliorating autoimmune diseases, whereas it induces activation of CD8(+) T cells, resulting in diverse therapeutic activity in cancer, viral infection. To investigate the CD137-mediated T cell suppression mechanism, we examined whether anti-CD137 mAb treatment could affect CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSCs). Intriguingly, anti-CD137 mAb injection significantly increased CD11b(+)Gr-1(+) cells, peaking at days 5 to 10 and continuing for at least 25 days. Furthermore, this cell population could suppress both CD8(+) T cells and CD4(+) T cells. Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce CD11b(+)Gr-1(+) MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.

No MeSH data available.


Related in: MedlinePlus

The kinetics of splenic CD11b+Gr-1+ cells due to anti-CD137 Ab treatment. The kinetic changes in percentage (A) and number (B) of splenic CD11b+Gr-1+ cells were measured after 300µg of anti-CD137 Ab i.p injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2902672&req=5

Figure 2: The kinetics of splenic CD11b+Gr-1+ cells due to anti-CD137 Ab treatment. The kinetic changes in percentage (A) and number (B) of splenic CD11b+Gr-1+ cells were measured after 300µg of anti-CD137 Ab i.p injection.

Mentions: Recent studies suggested that CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) in mice have been shown to accumulate in diverse pathological conditions including cancer, infectious diseases, sepsis, trauma, bone marrow transplantation and some autoimmune diseases, as well as inhibit the function of T cells (16). Therefore, we examined whether increased CD11b+Gr-1+ cells by anti-CD137 mAb treatment could induce characteristics of MDSCs. First, we checked the kinetic changes in CD11b+Gr-1+ cells after anti-CD137 mAb treatment. Single administration of 3H3 led to a significant increase in the CD11b+Gr-1+ cell population of splenocytes 5 days after treatment and continued for at least 25 days (Fig. 2A). The number of CD11b+Gr-1+ cells also increased by the treatment of anti-CD137 mAb and peaked at day 10 (Fig. 2B). Collectively, these data suggested that anti-CD137 mAb treatment could strongly induce the increase in CD11b+Gr-1+ cells.


Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11bGr-1 Myeloid-derived Suppressor Cells.

Lee JM, Seo JH, Kim YJ, Kim YS, Ko HJ, Kang CY - Immune Netw (2010)

The kinetics of splenic CD11b+Gr-1+ cells due to anti-CD137 Ab treatment. The kinetic changes in percentage (A) and number (B) of splenic CD11b+Gr-1+ cells were measured after 300µg of anti-CD137 Ab i.p injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2902672&req=5

Figure 2: The kinetics of splenic CD11b+Gr-1+ cells due to anti-CD137 Ab treatment. The kinetic changes in percentage (A) and number (B) of splenic CD11b+Gr-1+ cells were measured after 300µg of anti-CD137 Ab i.p injection.
Mentions: Recent studies suggested that CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) in mice have been shown to accumulate in diverse pathological conditions including cancer, infectious diseases, sepsis, trauma, bone marrow transplantation and some autoimmune diseases, as well as inhibit the function of T cells (16). Therefore, we examined whether increased CD11b+Gr-1+ cells by anti-CD137 mAb treatment could induce characteristics of MDSCs. First, we checked the kinetic changes in CD11b+Gr-1+ cells after anti-CD137 mAb treatment. Single administration of 3H3 led to a significant increase in the CD11b+Gr-1+ cell population of splenocytes 5 days after treatment and continued for at least 25 days (Fig. 2A). The number of CD11b+Gr-1+ cells also increased by the treatment of anti-CD137 mAb and peaked at day 10 (Fig. 2B). Collectively, these data suggested that anti-CD137 mAb treatment could strongly induce the increase in CD11b+Gr-1+ cells.

Bottom Line: Intriguingly, anti-CD137 mAb injection significantly increased CD11b(+)Gr-1(+) cells, peaking at days 5 to 10 and continuing for at least 25 days.Furthermore, this cell population could suppress both CD8(+) T cells and CD4(+) T cells.Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce CD11b(+)Gr-1(+) MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea.

ABSTRACT
CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T cells. However, agonistic anti-CD137 monoclonal antibody (mAb) treatment can suppress CD4(+) T cells, ameliorating autoimmune diseases, whereas it induces activation of CD8(+) T cells, resulting in diverse therapeutic activity in cancer, viral infection. To investigate the CD137-mediated T cell suppression mechanism, we examined whether anti-CD137 mAb treatment could affect CD11b(+)Gr-1(+) myeloid-derived suppressor cells (MDSCs). Intriguingly, anti-CD137 mAb injection significantly increased CD11b(+)Gr-1(+) cells, peaking at days 5 to 10 and continuing for at least 25 days. Furthermore, this cell population could suppress both CD8(+) T cells and CD4(+) T cells. Thus, this study demonstrated that, for the first time, anti-CD137 mAb treatment could induce CD11b(+)Gr-1(+) MDSCs under normal conditions, suggesting a possible relationship between myeloid cell induction and CD137-mediated immune suppression.

No MeSH data available.


Related in: MedlinePlus